DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Martin Currie Ltd.

Martin Currie Ltd. decreased its stake in DexCom, Inc. (NASDAQ:DXCM) by 15.5% during the 1st quarter, Holdings Channel reports. The firm owned 95,071 shares of the medical device company’s stock after selling 17,412 shares during the quarter. Martin Currie Ltd.’s holdings in DexCom were worth $6,492,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Aberdeen Group plc raised its stake in DexCom by 3.8% during the first quarter. Aberdeen Group plc now owns 360,724 shares of the medical device company’s stock worth $24,311,000 after purchasing an additional 13,173 shares during the period. Liontrust Investment Partners LLP raised its stake in DexCom by 2.9% during the first quarter. Liontrust Investment Partners LLP now owns 100,259 shares of the medical device company’s stock worth $6,847,000 after purchasing an additional 2,812 shares during the period. Horizon Investments LLC raised its stake in DexCom by 2.2% during the first quarter. Horizon Investments LLC now owns 5,608 shares of the medical device company’s stock worth $383,000 after purchasing an additional 123 shares during the period. Fox Run Management L.L.C. raised its stake in DexCom by 175.5% during the first quarter. Fox Run Management L.L.C. now owns 8,533 shares of the medical device company’s stock worth $583,000 after purchasing an additional 5,436 shares during the period. Finally, Trivium Point Advisory LLC raised its stake in DexCom by 6.1% during the first quarter. Trivium Point Advisory LLC now owns 3,455 shares of the medical device company’s stock worth $236,000 after purchasing an additional 200 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and set a $106.00 target price on shares of DexCom in a research note on Friday, August 1st. Wall Street Zen downgraded shares of DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, August 10th. Truist Financial initiated coverage on shares of DexCom in a research note on Monday, June 16th. They set a “buy” rating and a $102.00 target price on the stock. Oppenheimer boosted their price target on shares of DexCom from $95.00 to $102.00 and gave the company an “outperform” rating in a research note on Thursday, July 31st. Finally, William Blair raised shares of DexCom to a “strong-buy” rating in a research note on Thursday, July 31st. Four research analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $99.89.

Insider Activity

In related news, EVP Sadie Stern sold 6,184 shares of the stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total value of $526,320.24. Following the sale, the executive vice president directly owned 109,621 shares of the company’s stock, valued at approximately $9,329,843.31. This represents a 5.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Michael Jon Brown sold 10,000 shares of the stock in a transaction dated Friday, May 23rd. The shares were sold at an average price of $84.28, for a total transaction of $842,800.00. Following the completion of the sale, the executive vice president directly owned 95,602 shares in the company, valued at approximately $8,057,336.56. The trade was a 9.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 28,656 shares of company stock worth $2,412,191 in the last 90 days. Corporate insiders own 0.32% of the company’s stock.

DexCom Stock Performance

Shares of DexCom stock opened at $79.96 on Friday. The company has a fifty day simple moving average of $83.17 and a 200-day simple moving average of $80.14. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $93.25. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. The stock has a market cap of $31.36 billion, a price-to-earnings ratio of 55.53, a PEG ratio of 1.68 and a beta of 1.43.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, topping analysts’ consensus estimates of $0.45 by $0.03. The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. DexCom’s quarterly revenue was up 15.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.43 EPS. On average, equities analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.